98%
921
2 minutes
20
Background: Severe aortic stenosis (AS) has been associated with bleeding. However, there is a lack of prospective assessment of bleeding events and their clinical significance in a large population of outpatients with variable degree of AS severity.
Objectives: To assess the incidence, source, determinants, and prognostic impact of major bleeding in patients with variable degree of AS severity.
Methods: Between May 2016 and December 2017, consecutive outpatients were included. Major bleeding was defined as type ≥3 bleed using the Bleeding Academic Research Consortium definition. Cumulative incidence was calculated with death as the competing event. Data was censored at time of aortic valve replacement.
Results: Among 2,830 patients, 46 major bleeding events occurred (0.7%/year) during a median follow-up of 2.1 years (interquartile range: 1.4-2.7). Most frequent sites of bleeding were gastrointestinal (50%) and intracranial (30.4%). Major bleeding was significantly associated with all-cause mortality (hazard ratio: 5.93 (95% confidence interval 3.64-9.65); P < .001). AS severity was associated with major bleedings (P = .041). By multivariable analysis, severe AS was an independent determinant of major bleeding (hazard ratio vs mild AS: 3.59 [95% confidence interval 1.56-8.29]; P = .003). The increased risk of bleeding associated with severe AS was significantly exacerbated in patients using oral anticoagulation.
Conclusion: In AS patients, major bleeding is rare but a strong independent predictor of death. AS severity is a determinant of bleeding events. Severe AS and oral anticoagulation should be identified as an association at very high risk of major bleeding.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ahj.2023.04.011 | DOI Listing |
Hepatology
September 2025
Department of Gastroenterology and Hepatology, UT Southwestern, Dallas, TX.
Background: The clinical course and outcomes of alcohol-associated hepatitis (AH) remain poorly understood. Major adverse liver outcomes (MALO) do not capture the added risk of return to drinking (RTD). We examined the natural history of AH and developed a composite endpoint using a contemporary observational cohort of AH.
View Article and Find Full Text PDFKhirurgiia (Mosk)
September 2025
Vishnevsky National Medical Research Center of Surgery, Moscow, Russia.
Objective: To demonstrate the effectiveness and safety of intraluminal endoscopic treatment of patients with adenomas of the major duodenal papilla and familial adenomatous polyposis.
Material And Methods: Over the past 4 years, 13 patients with adenomas of the major duodenal papilla and familial adenomatous polyposis underwent surgery in our hospital. Of these, 7 patients had exclusively extrapapillary adenomas without signs of spread to the ducts.
Background: Data on the levels of rivaroxaban-specific anti-factor Xa activity (AFXaA) within three weeks of starting high-dose rivaroxaban therapy in patients with cancer-associated thromboembolism (CAT) is limited. This study aimed to determine initial levels of rivaroxaban-specific AFXaA in patients with CAT to assist with drug monitoring.
Methods: This study included a total of 33 patients from December 2017 through January 2019.
Laryngoscope
September 2025
UCSF Voice & Swallowing Center, Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California, USA.
Objectives: In patients with significant upper airway stenosis, airway compromise can occur associated with general anesthesia (GA). A previous study demonstrated the feasibility of awake laser laryngeal stenosis surgery (ALLSS) in the operating room (OR) in five patients. This study sought to determine patient outcomes of ALLSS.
View Article and Find Full Text PDFCatheter Cardiovasc Interv
September 2025
Escuela de Medicina, Universidad Peruana Unión, Lima, Peru.
Background: Current guidelines recommend clopidogrel in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI), yet the comparative benefits are unclear.
Aims: The aim of this study was to evaluate the efficacy and safety of ticagrelor versus clopidogrel in patients with CCS undergoing PCI.
Methods: We searched PubMed/MEDLINE, EMBASE, CENTRAL databases from inception to February 15, 2025.